GlassScriptPhysician profile
Laura Atkinson
NPI 1912630146
$3,580.97
in general payments reported to CMS, 2019-2025
27 companies · $2,091 in 2025
The $2,091 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $823 · 2023: $653 · 2024: $14.25 · 2025: $2,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,679 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,679.38 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $665.13 | 2022-2023 | Mounjaro, Trulicity, Jardiance |
| Abbvie INC. | $406.37 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $283.59 | 2025 | Zenpep, Vowst |
| Janssen Biotech, INC. | $246.09 | 2025 | Tremfya, Simponi, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $244.19 | 2022-2025 | Entyvio, Eohilia, Cuvitru |
| Pfizer INC. | $226.53 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $219.63 | 2025 | Voquezna |
| Ardelyx, INC. | $187.47 | 2025 | Ibsrela |
| Novo Nordisk INC | $133.42 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Intuitive Surgical, INC. | $132.80 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.51 | 2023-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $127.40 | 2022-2023 | Rexulti |
| Pinnacle Biologics, INC | $105.02 | 2025 | Photofrin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.35 | 2022-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $67.70 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $53.46 | 2022 | |
| Intercept Pharmaceuticals, INC. | $36.05 | 2025 | |
| Glaxosmithkline, LLC. | $34.73 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $32.58 | 2022-2023 | Steglatro |
| Genzyme Corporation | $25.42 | 2025 | |
| Qol Medical, LLC | $25.14 | 2025 | Sucraid |
| Biohaven Pharmaceutical Holding Company LTD. | $24.84 | 2022 | |
| Vivus LLC | $19.79 | 2025 | Pancreaze |
| Celltrion USA INC. | $18.85 | 2025 | Vegzelma |
| Idorsia Pharmaceuticals US INC | $15.98 | 2022 | |
| Mylan Specialty L.P. | $15.29 | 2023 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $13.64 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Atkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.